Data on long-term outcomes and biological drivers associated with depth of remission after
BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are …

During apoptosis, the BCL‐2‐family protein tBID promotes mitochondrial permeabilization
by activating BAX and BAK and by blocking anti‐apoptotic BCL‐2 members. Here, we report …

Therapy-resistant microenvironments represent a major barrier toward effective elimination
of disseminated malignancies. Here, we show that select microenvironments can underlie …

Deciphering the evolution of cancer cells under therapeutic pressure is a crucial step to
understand the mechanisms that lead to treatment resistance. To this end, we analyzed whole-…

MicroRNAs (miRNA) play a key role in cellular regulation and, if deregulated, in the
development of neoplastic disorders including chronic lymphocytic leukemia (CLL). RNAs from …

Dysregulated microRNA (miRNA) expression contributes to the pathogenesis of hematopoietic
malignancies, including chronic lymphocytic leukemia (CLL). However, an understanding …

The effects of two CD20 antibodies, namely rituximab, the current standard for treatment of
chronic lymphocytic leukaemia (CLL) in combination with chemotherapy, and GA101, a glyco‐…

Mechanism-oriented studies of EAE rely mostly on gene-modified mice on the C57BL/6
background. Here we report that MP4-induced EAE displays characteristic differences in CNS …

In chronic lymphocytic leukemia (CLL), the median age at diagnosis is 72 years, and most
patients requiring therapy have coexisting medical conditions. Venetoclax is a potent BH3-…

The adaptor protein MYD88 is critical for relaying activation of Toll-like receptor signaling to
NF-κB activation. MYD88 mutations, particularly the p.L265P mutation, have been described …